01/04
Headlines

NPS Pharmaceuticals

FB Nasdaq FB Facebook

Healthcare Gainers: BioScrip Inc (NASDAQ:BIOS), NPS Pharmaceuticals (NASDAQ:NPSP), RadNet Inc. (NASDAQ:RDNT), Avanir Pharmaceuticals Inc (NASDAQ:AVNR)

Richard Atkins02 mins

BioScrip Inc (NASDAQ:BIOS), on May 8, 2014 announced 2014 first quarter financial results. First quarter revenue from continuing operations was $239.6 million and the net loss from continuing operations was $25.4 million, or $0.37 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.13.BioScrip Inc (NASDAQ:BIOS) stock…

Read More

Biotech Top Gainers: OXiGENE Inc (NASDAQ:OXGN), Cell Therapeutics Inc (NASDAQ:CTIC), Arca Biopharma Inc (NASDAQ:ABIO), NPS Pharmaceuticals (NASDAQ:NPSP)

Jason Knox02 mins

Biopharmaceutical giant Oxigene Inc (NASDAQ:OXGN) y reported its experimental drug Zybrestat, combined with Roche’s cancer drug Avastin, significantly slowed progression of recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN) stock performance was 77.27% in last session and finished the day at $4.29. Traded volume was 29,290,814 million shares in the last session and the average volume of…

Read More

Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Insys Therapeutics (NASDAQ:INSY), NPS Pharmaceuticals (NASDAQ:NPSP), XOMA Corp (NASDAQ:XOMA)

Richard Atkins02 mins

The Rosen Law Firm, P.A. reminds purchasers of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”) of the important Mach 17, 2014 lead plaintiff deadline in the class action seeking remedies under the federal securities laws. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) stock performance was -5.40% in last session…

Read More